Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13081164 | 0.89 | CA1 (0.30) | CA1CA2CA9ELANE | |
| SCHEMBL13053797 | 0.88 | ALDH1A1 (0.32) | — | |
| SCHEMBL12712739 | 0.86 | — | — | |
| SCHEMBL13081513 | 0.84 | — | — | |
| SCHEMBL13053806 | 0.83 | — | — | |
| SCHEMBL13081392 | 0.82 | CA2 (0.39) | CA1CA2CA9ELANEL3MBTL1 | |
| SCHEMBL26668874 | 0.81 | ALDH1A1 (0.39) | CA1CA2CA9ELANEL3MBTL1 | |
| SCHEMBL15989468 | 0.81 | ALDH1A1 (0.39) | CA1CA2CA9ELANEL3MBTL1 | |
| SCHEMBL13053732 | 0.80 | TMEM97 (0.32) | CA1CA2CA9ELANEL3MBTL1 | |
| SCHEMBL13053855 | 0.80 | CA1 (0.34) | CA1CA2CA9ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170912-B3 | NEW PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | CENTRE NAT RECH SCIENT (FR) | 2022-06-15 | — | — | EP | disclosed |
| US-8383609-B2 | Phosphorus containing heterocyclic compounds, sugar analogues, and compositions having anti-cancer activity containing the same | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2013-02-26 | — | — | US | disclosed |
| US-20100298272-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-11-25 | — | — | US | disclosed |
| US-20100298272-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298272-A1 | PHOSPHORUS CONTAINING HETEROCYCLIC COMPOUNDS, SUGAR ANALOGUES, AND COMPOSITIONS HAVING ANTI-CANCER ACTIVITY CONTAINING THE SAME | G6PC1, SLC5A1, HK1 | CA1 494/4885CA2 182/4885CA9 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.